Modern trends in anti-VEGF therapy for age-related macular degeneration

Budzinskaya, M.V.; Plyukhova, A.A.; Alkharki, L.

doi:10.17116/oftalma202313903246

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abciximab and compeximab, on the other hand, are recombinant anti-VEGF fusion proteins, distinguishing them from the monoclonal antibodies mentioned above [104,105] . Abciximab, following bevacizumab, is another anti-VEGF antibody drug with a broader spectrum of action.…”

Section: Anti-vegf Antibodiesmentioning

confidence: 99%

“…Pegaptanib exclusively targets the 165 subtype of VEGFA, whereas ranibizumab acts on the entire VEGFA target. Due to its limited efficacy, pegaptanib was withdrawn from the market [104] . Indeed, in practical applications, the search for aptamers that are well-suited to specific targets within databases can be a significant challenge.…”

Section: Anti-vegf Aptamersmentioning

confidence: 99%

See 1 more Smart Citation

Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future Prospects

Zhang,

Lu,

et al. 2023

Preprint

View full text Add to dashboard Cite

Abnormal ocular angiogenesis is a key factor in the development of many blinding ocular diseases, including wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), pathologic myopia with choroidal neovascularization (PM-CNV), and neovascular glaucoma (NVG). The development of anti-neovascular drugs and ocular drug delivery systems (DDS) offers more possibilities for the treatment of neovascular eye diseases. In addition to anti-vascular endothelial growth factor (anti-VEGF) agents, the discovery of other anti-angiogenic targets, such as somatostatin, endostatin and pigment epithelium-derived factor (PEDF), has been a boon to patients with poor anti-VEGF efficacy and led to a reduction in the adverse effects of long-term VEGF inhibition. Gene therapy is currently a very promising approach for the treatment of neovascular ophthalmopathy. The rapid development of gene therapy and the potential for viral vector-mediated gene delivery to achieve sustained expression of anti-vascular substances at the lesion site will mitigate the risks associated with frequent intraocular injections for patients. This review provides an overview of several neovascular ophthalmopathies, discusses the use of anti-vascular therapeutic agents and common DDS, and summarizes treatment strategies and future perspectives for neovascular ophthalmopathy.

show abstract

Section: Anti-vegf Antibodiesmentioning

confidence: 99%

Section: Anti-vegf Aptamersmentioning

confidence: 99%